Condition
GI Cancers
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Withdrawn1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07387263Not ApplicableRecruiting
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
NCT07216560Phase 1RecruitingPrimary
First-in-human Study of 7MW4911 in GI Cancer
NCT06648785Phase 2Enrolling By InvitationPrimary
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies
NCT05044312Not ApplicableWithdrawnPrimary
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
Showing all 4 trials